Superior semicircular canal dehiscence and an abnormally wide internal auditory meatus are clinical entities characterized by vestibular and cochlear symptoms. These symptoms are induced by hypersensitivity of labyrinthine receptors secondary to a bone defect of the otic capsule. We report the case of a 41-year-old man with congenital right-sided hearing loss who presented with bilateral superior semicircular canal dehiscence that was associated with wide, bulbous internal auditory meatus and a loss of the bony wall separating the lateral end of the meatus from the cochlea. The patient was experiencing vestibular and cochlear symptoms in the right ear and disabling tinnitus in the left ear. However, he refused all treatment and was lost to follow-up. Figure 3. Sagittal CTs show the SSCDs in the right (A) and left (B) ears.
Introduction
Congenital hearing loss can be accompanied by radiologically demonstrable bony inner ear abnormalities associated with narrow internal auditory meatus. Most reports in the literature about dilated internal auditory meatus refer to expansion secondary to an acoustic neuroma or other occupying lesion.
The width of the internal auditory meatus is variable. Tomura et al considered a horizontal diameter of more than 0.8 mm in the middle portion of the canal as abnormally large. 1 In their series of 325 patients, the prevalence of such an abnormality was 2.3%. They also emphasized that the presence of a crista falciformis and a normal cortical outline were important factors in differentiating an abnormally large internal auditory meatus from a "normal variant. " 2 In 1999, Birman and Gibson reported on their study of 5 children in which they found that a wide internal auditory canal might be associated with a partial dehiscence of the lateral fundus and other temporal bone abnormalities. 3 They wrote that such a widening may increase the degree of communication between the internal auditory canal and the inner ear, which may herald a progressive or fluctuating sensorineural hearing loss (SNHL). In a study of 247 children published in 2002, McClay et al reported no significant difference in the prevalence of a wide internal auditory canal between children with SNHL and those without. 4 In this article we report a new case of large bilateral internal auditory meatus, and we discuss the possibility that a developmental abnormality underlies superior semicircular canal dehiscence (SSCD) syndrome.
Case report
A 41-year-old man was referred to our tertiary care otoneurology center for evaluation of dizziness, oscillopsia, deafness in the right ear, and disabling tinnitus in the presence of normal hearing in the left ear.
A close case history determined that the dizziness was evoked by loud sounds (Tullio phenomenon) and the oscillopsia was related to intense exertion. The patient did not recall having experienced any closed cranial trauma.
After findings on otoscopy were normal, the patient underwent evaluation with a standardized set of tests, including bedside video-oculography. During the latter evaluation, the patterns of horizontal, torsional, and vertical eye movements were recorded on a threedimensional infrared video-oculograph recorder (50-Hz sampling; Torsio VideoNystagmoGraphy Ulmer; Synapsys; Marseille, France). The investigated parameters included spontaneous nystagmus, head-shaking nystagmus, positional nystagmus during the Dix-Hallpike ENT-Ear, Nose & Throat Journal  January 2013 and head-roll maneuvers, nystagmus with the Valsalva maneuver, the Tullio phenomenon after hyperventilation and exposure to 3 kHz at 110 dB, and eye movements after mastoid vibration at 100 Hz.
The patient then underwent specific audiovestibular testing. Caloric stimulation with the Fitzgerald-Hallpike test elicited a normal pattern. Cervical vestibular evoked myogenic potential testing was carried out with a tone burst of 500 Hz lasting 2 msec and a repetition frequency of 4 Hz 100 times. With these parameters, a clearly detectable response would be expected at 95 dB normal hearing level (NHL), while no response would be detected at less than 80 dB NHL. These values, which have been proven to be reliable in our laboratory, are generally accepted as standard values under the conditions described.
In our patient, we found bilateral lowering of the detection threshold, with the p13-n23 complex being evoked by 65 and 70 dB NHL stimuli on the right and left sides, respectively. Stapedial reflexes were present. An auditory brainstem response was absent in the right ear and normal in the left ear.
Based on these findings, we referred the patient to a tertiary care radiology center for magnetic resonance imaging (MRI) of the posterior cranial fossa with paramagnetic contrast enhancement. MRI revealed an abnormal symmetric volumetric increase of the VIIIth cranial nerve (figure 1). In view of the results of cervical vestibular evoked myogenic potentials testing, it then seemed appropriate to obtain high-resolution computed tomography (CT).
CT confirmed the abnormally wide internal auditory meatus bilaterally (figure 2). CT also showed a loss of the bony wall separating the lateral end of the meatus from the cochlea, and it identified bilateral SSCD (figure 3). These findings were fundamental in explaining our patient's vestibular symptoms.
The patient refused all treatment options and was lost to follow-up.
Discussion
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Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract, untreated local or systemic fungal or bacterial infections, systemic viral or parasitic infections, or ocular herpes simplex because of the potential for worsening of these infections.
Hypothalamic-Pituitary-Adrenal Axis Effect
When intranasal steroids are used at higher-than-recommended dosages or in susceptible individuals at recommended dosages, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of QNASL Nasal Aerosol should be discontinued slowly, consistent with accepted procedures for discontinuing oral corticosteroid therapy.
The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency. In addition, some patients may experience symptoms of corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, and depression). Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress. In patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, rapid decreases in systemic corticosteroid dosages may cause a severe exacerbation of their symptoms.
Effect on Growth
Corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Routinely monitor the growth of pediatric patients receiving QNASL Nasal Aerosol [see Use in Specific Populations (8.4) ].
ADVERSE REACTIONS
Systemic and local corticosteroid use may result in the following: 
Clinical Trials Experience
The safety data described below for adults and adolescents 12 years of age and older with seasonal or perennial allergic rhinitis are based on 4 placebo-controlled clinical trials of 2 to 6 weeks duration evaluating doses of beclomethasone nasal aerosol from 80 to 320 mcg once daily. These short-term trials included a total of 1394 patients with either seasonal or perennial allergic rhinitis. Of these, 575 (378 female and 197 male) received at least one dose of QNASL Nasal Aerosol, 320 mcg once daily and 578 (360 female and 218 male) received placebo. Patient ages ranged from 12 to 82 years and the racial distribution of patients was 81% white, 16% black, and 4% other.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Short-Term (2-6 Weeks) Trials: Overall, the incidence of adverse reactions did not differ appreciably between patients treated with QNASL Nasal Aerosol and those who were treated with placebo. Less than 2% of patients in the clinical trials discontinued treatment because of adverse reactions with the rate of withdrawal among patients who received QNASL Nasal Aerosol similar to or lower than the rate among patients who received placebo. Table 1 displays the common adverse reactions (≥1% and greater than placebo-treated patients). Nasal ulcerations occurred in 2 patients treated with placebo and in 1 patient treated with QNASL Nasal Aerosol. There were no differences in the incidence of adverse reactions based on gender or race. Clinical trials did not have sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients.
Long-Term 52-Week Safety Trial: In a 52-week placebo-controlled long-term safety trial in patients with PAR, 415 patients (128 males and 287 females, aged 12 to 74 years) were treated with QNASL Nasal Aerosol at a dose of 320 mcg once daily and 111 patients (44 males and 67 females, aged 12 to 67 years) were treated with placebo. Of the 415 patients treated with QNASL Nasal Aerosol, 219 patients were treated for 52 weeks and 196 patients were treated for 30 weeks. While most adverse events were similar in type and rate between the treatment groups, epistaxis occurred more frequently in patients who received QNASL Nasal Aerosol (45 out of 415, 11%) than in patients who received placebo (2 out of 111, 2%). Epistaxis also tended to be more severe in patients treated with QNASL Nasal Aerosol. In 45 reports of epistaxis in patients who received QNASL Nasal Aerosol, 27, 13, and 5 cases were of mild, moderate, and severe intensity, respectively, while
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INDICATIONS AND USAGE 1.Treatment of Nasal Symptoms of Allergic Rhinitis
QNASL Nasal Aerosol is indicated for the treatment of the nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
CONTRAINDICATIONS
QNASL Nasal Aerosol is contraindicated in patients with a history of hypersensitivity to beclomethasone dipropionate and/or any other QNASL Nasal Aerosol ingredients [see Warnings and Precautions (5.3)].
WARNINGS AND PRECAUTIONS 5.1 Local Nasal Effects
Nasal Discomfort, Epistaxis, and Nasal Ulceration: In clinical trials of 2 to 52 weeks duration, epistaxis and nasal ulcerations were observed more frequently and some epistaxis events were more severe in patients treated with QNASL Nasal Aerosol than those who received placebo. In the 52-week safety trial in patients with perennial allergic rhinitis, nasal erosions were identified in 4 of 415 patients and a nasal ulceration was identified in 1 of 415 patients treated with QNASL Nasal Aerosol. No nasal erosions or ulcerations were reported for patients who received placebo. Patients using QNASL Nasal Aerosol over several months or longer should be examined periodically for possible changes in the nasal mucosa. If an adverse reaction (e.g., erosion, ulceration) is noted, discontinue QNASL Nasal Aerosol. [see Adverse Reactions (6.1)].
Candida Infection: In previous clinical trials with an aqueous formulation of beclomethasone dipropionate administered intranasally, localized infections of the nose and pharynx with Candida albicans had been reported. There were no instances of similar infections observed in clinical trials with QNASL Nasal Aerosol. If such an infection develops, it may require treatment with appropriate local therapy and discontinuation of QNASL Nasal Aerosol treatment. Thus, patients using QNASL Nasal Aerosol over several months or longer should be examined periodically for evidence of Candida infection. Nasal Septal Perforation: Instances of nasal septal perforation have been reported in patients following the intranasal application of beclomethasone dipropionate. There were no instances of nasal septal perforation observed in clinical trials with QNASL Nasal Aerosol. Impaired Wound Healing: Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use QNASL Nasal Aerosol until healing has occurred.
Glaucoma and Cataracts
Use of intranasal and inhaled corticosteroids may result in the development of glaucoma and/or cataracts. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.
Glaucoma and cataract formation was evaluated with ocular assessments that included intraocular pressure measurements and slit lamp examinations in 245 adolescent and adult patients (12 years of age and older) with perennial allergic rhinitis who were treated with QNASL Nasal Aerosol 320 mcg daily (N=197) or placebo (N=48) for up to 52 weeks. In 94% of patients, intraocular pressure (IOP) remained within the normal range (<21 mmHg) during the treatment portion of the trial. There were 10 patients (5%) treated with QNASL Nasal Aerosol and 1 patient (2%) treated with placebo that had intraocular pressure that increased above normal levels (≥21 mmHg) and greater than baseline during the treatment portion of the trial. Two of these occurrences in patients treated with QNASL Nasal Aerosol were reported as adverse reactions, one serious. No instances of cataract formation or other clinically significant ocular incidents were reported in this 52-week safety trial [see Adverse Reactions (6.1)].
Hypersensitivity Reactions Including Anaphylaxis
Hypersensitivity reactions including anaphylaxis, angioedema, urticaria, and rash have been reported following administration of beclomethasone dipropionate nasally administered and inhalationally administered products. Angioedema, urticaria, and rash have been reported following administration of QNASL Nasal Aerosol. Discontinue QNASL Nasal Aerosol if any such reactions occur [see Contraindications (4) ].
Immunosuppression
Persons who are using drugs that suppress the immune system (e.g., corticosteroids) are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If a patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated (see the respective package inserts for complete VZIG and IG prescribing information). If chickenpox or measles develops, treatment with antiviral agents may be considered. the reports of epistaxis in patients who received placebo were of mild (1) and moderate (1) intensity. Seventeen patients treated with QNASL Nasal Aerosol experienced adverse reactions that led to withdrawal from the trial compared to 3 patients treated with placebo. There were 4 nasal erosions and 1 nasal septum ulceration which occurred in patients who received QNASL Nasal Aerosol, and no erosions or ulcerations noted in patients who received placebo. No patient experienced a nasal septum perforation during the trial.
Postmarketing Experience
In addition to adverse reactions reported from clinical trials for QNASL Nasal Aerosol, the following adverse events have been reported during use of other intranasal and inhaled formulations of beclomethasone dipropionate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to beclomethasone dipropionate or a combination of these factors.
Intranasal beclomethasone dipropionate: Nasal septal perforation, glaucoma, cataracts, loss of taste and smell, and hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported following intranasal administration of beclomethasone dipropionate.
Inhaled beclomethasone dipropionate: Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, and bronchospasm have been reported following the oral inhalation of beclomethasone dipropionate.
DRUG INTERACTIONS
No drug interaction studies have been performed with QNASL Nasal Aerosol.
USE IN SPECIFIC POPULATIONS 8.1 Pregnancy
Teratogenic Effects: Pregnancy Category C There are no adequate and well-controlled clinical trials in pregnant women treated with QNASL Nasal Aerosol. Beclomethasone dipropionate was teratogenic and embryocidal in the mouse and rabbit although these effects were not observed in rats. QNASL Nasal Aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Experience with oral corticosteroids since their introduction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.
Beclomethasone dipropionate administered subcutaneously was teratogenic and embryocidal in the mouse and rabbit at doses approximately twice the maximum recommended human daily intranasal dose (MRHDID) in adults (on a mg/m 2 basis at maternal doses of 0.1 and 0.025 mg/kg/day in mice and rabbits, respectively). No teratogenicity or embryocidal effects were seen in rats at approximately 460 times MRHDID (in adults on a mg/m 2 basis at a maternal inhalation dose of 15 mg/kg/day).
Non-teratogenic Effects: Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully monitored.
Nursing Mothers
It is not known whether beclomethasone dipropionate is excreted in human breast milk. However, other corticosteroids have been detected in human breast milk and thus caution should be exercised when QNASL Nasal Aerosol is administered to a nursing mother.
Pediatric Use
The safety and effectiveness for seasonal and perennial allergic rhinitis in children 12 years of age and older have been established. Controlled clinical trials with QNASL Nasal Aerosol included 188 adolescent patients 12 to 17 years of age [see Clinical Studies (14) ]. The safety and effectiveness of QNASL Nasal Aerosol in children younger than 12 years of age have not been established.
Controlled clinical trials have shown that intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA-axis function. The long-term effects of reduction in growth velocity associated with intranasal corticosteroids, including the impact on final adult height, are unknown. The potential for "catch-up" growth following discontinuation of treatment with intranasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving intranasal corticosteroids, including QNASL Nasal Aerosol, should be monitored routinely (e.g., via stadiometry).
A 12-month, randomized, controlled clinical trial evaluated the effects of QVAR ® , an orally inhaled HFA beclomethasone dipropionate product, without spacer versus chlorofluorocarbon-propelled (CFC) beclomethasone dipropionate with large volume spacer on growth in children with asthma ages 5 to 11 years. A total of 520 patients were enrolled, of whom 394 received HFA-beclomethasone dipropionate (100 to 400 mcg/day ex-valve) and 126 received CFC-beclomethasone dipropionate (200 to 800 mcg/day ex-valve). When comparing results at month 12 to baseline, the mean growth velocity in children treated with HFA-beclomethasone dipropionate was approximately 0.5 cm/year less than that noted with children treated with CFC-beclomethasone dipropionate via large volume spacer. The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks/benefits of treatment alternatives.
The potential for QNASL Nasal Aerosol to cause reduction in growth velocity in susceptible patients or when given at higher than recommended dosages cannot be ruled out.
Geriatric Use
Clinical trials of QNASL Nasal Aerosol did not include sufficient numbers of subjects aged 65 years and older to determine whether they responded differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, administration to elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
OVERDOSAGE
Chronic overdosage may result in signs/symptoms of hypercorticism [see Warnings and Precautions (5.5) ]. There are no data available on the effects of acute or chronic overdosage with QNASL Nasal Aerosol. cochlear symptoms induced by hypersensitivity of the labyrinthine receptors secondary to a bony defect. 9 In their review, these defects were usually located in the external wall of the superior semicircular canal. The diagnosis of this disorder is based on the presence of characteristic symptoms such as dizziness, the Tullio phenomenon, positional vertigo, pulsatile tinnitus, and conductive and/or sensorineural hearing loss. SSCD syndrome should be suspected in the presence of the Hennebert sign (nystagmus induced by the Valsalva maneuver), and the diagnosis can be confirmed by the results of vestibular evoked myogenic potentials with threshold analysis in response to air-conducted sounds. 8, 10 Final confirmation of the diagnosis is obtained by high-resolution CT with parasagittal reconstruction of the circumference of the superior semicircular canal.
Gadolinium-enhanced MRI is the gold standard for making an imaging diagnosis of cerebellopontine angle lesions. High-resolution, fast-spin-echo, T2-weighted MRI is extremely useful for evaluating SNHL and intracanal lesions, and it is helpful in conjunction with CT in providing diagnostic information for genetic and lifestyle counseling.
The etiology of SSCD is controversial. The independent development of the individual semicircular canals in relation to the cochlea and vestibule is a complex embryologic process rather than merely a case of arrested development. 11 SSCD might also be caused by an abnormal vascular anatomy, and as such it sometimes presents late in life without any precipitating event. 10, 12, 13 SSCDs can cause (1) a significant reduction in soundinduced round-window velocity at low frequencies, (2) small but significant increases in sound-induced stapes and umbo velocities, and (3) a measurable fluid velocity inside the dehiscence. Findings from cadaveric temporal-bone studies have supported the "third window" hypothesis. 14 Our patient presented with bilateral lesions and no history of trauma, which supports the hypothesis that congenital and/or genetic factors may be involved. 15 Our case should also alert clinicians to the associations between auditory and vestibular symptoms.
In the absence of any previous reports of such cases, we believe that it is important to obtain MRI and CT in order to establish a diagnosis and a differential diagnosis (e.g., posterior semicircular canal dehiscence in patients presenting with vertigo and SNHL 16 ), and to provide lifestyle counseling.
The management of SSCD syndrome involves conservative and surgical approaches. Surgical options for patients with disabling vestibular symptoms include either a middle fossa craniotomy 17 or a transmastoid superior semicircular canal occlusion. 18 Primary middle fossa and transmastoid superior semicircular canal occlusions are not associated with SNHL, and in some cases they can lead to normalization of a conductive hearing loss. 17, 18 Indeed, in our opinion, surgery was not recommended for our patient because hearing was present in only one ear.
A thorough review of the English-language literature suggests that this is the first report of bilateral SSCD associated with bilateral large internal auditory meatus. The bilateral nature of our patient's condition speaks in favor of a developmental abnormality or a more complex (albeit mild) embryologic process as the cause, 11 as has already been suggested. 19 large bilateral iNterNal auditory meatus associated with bilateral superior semicircular caNal dehisceNce the foreign body represent the conventional treatment for nontuberculous mycobacterial otomastoiditis, but only when effective antimicrobial therapy is also administered. 11, 21 
